Insights That Move the GPCR Field Forward

👉 Strong biotech startups do not fail because the science is weak or the team is incapable. They fail when the pressure of fundraising slowly starts reshaping how decisions are made , long before anyone notices that strategy has begun to drift. In early-stage biotech, fundraising rarely feels like a strategic threat. It feels like a necessary distraction. Founders tell themselves that certain compromises are temporary, that clarity will return after the round closes. 👉 What

Most biotech founders assume that failure comes from making the wrong call. A flawed experiment. A bad hire. A missed partnership. 👉 Biotech startup failure is usually imagined as a moment where something clearly breaks. In reality, many biotech startups drift into trouble without ever making a single decision that looks wrong at the time. Progress continues. Data improves. Teams stay busy. And yet, momentum slowly fades. 👉 This is what makes biotech startup failure so diff

Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence